Phenotype of BTK-lacking myeloid cells during prolonged COVID-19 and upon convalescent plasma

Eur J Haematol. 2023 Feb;110(2):209-212. doi: 10.1111/ejh.13881. Epub 2022 Oct 19.

Abstract

XLA patient with 7-month course of COVID-19 with persistent plasma SARS-CoV-2 load revealed a sustained non-inflammatory profile of myeloid cells in association with contained severity of disease, arguing in favor of the use of BTK inhibitors in SARS-COV-2 infection.

Keywords: BTK; COVID-19; SARS-CoV-2; X-linked agammaglobulinemia; innate immunity; monocytes.

Publication types

  • Case Reports

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase / genetics
  • COVID-19 Serotherapy
  • COVID-19*
  • Genetic Diseases, X-Linked*
  • Humans
  • Myeloid Cells
  • Phenotype
  • Protein-Tyrosine Kinases
  • SARS-CoV-2

Substances

  • Protein-Tyrosine Kinases
  • Agammaglobulinaemia Tyrosine Kinase